Clinical Innovations, Inc. dba CITrials

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Bipolar disorder3 trials
• Obesity3 trials
• Type 2 diabetes2 trials
• Schizophrenia1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Recruiting4 trials
• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• Bristol-Myers Squibb3 trials
• Pfizer3 trials
• Minerva Neurosciences1 trial

Running trials

• Recruiting

  Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

  NCT07565428· Phase 3· Minerva Neurosciences· Source

  Contact: Chief Operating Officer

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Pfizer· Source

• Active, not recruiting

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  NCT07140913· Phase 3· Bristol-Myers Squibb· Source

  Contact: Evagelos Coskinas, Site 0106

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Bristol-Myers Squibb· Source

  Contact: Evagelos Coskinas, Site 0043

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

  NCT06951711· Phase 3· Bristol-Myers Squibb· Source

  Contact: Evagelos Coskinas, Site 0018

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bipolar disorder3 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

  NCT06897202· Phase 2· Pfizer· Source